Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Participants were treated until progressive disease, unacceptable toxicity, or participant's
refusal of further study treatment. All participants were followed when on study treatment
and after completion of study treatment during follow up period until death or the study
cutoff date, whichever come first.

Inclusion criteria :

- I 01. Histologically- or cytologically-confirmed prostate adenocarcinoma.

- I 02. Metastatic disease.

- I 03. Progressive disease while receiving hormonal therapy or after surgical
castration.

- I 04. Effective castration (serum testosterone levels ≤0.50 ng/mL) by orchiectomy
and/or luteinizing hormone-releasing hormone (LHRH) agonists or antagonist with or
without anti-androgens.

Exclusion criteria:

- E 01. Prior chemotherapy for prostate cancer,

- E 02. Less than 28 days elapsed from prior treatment with estramustine, radiotherapy
or surgery to the time of randomization. Participants on biphosphonates prior to study
entry.

- E 03. Prior isotope therapy, whole pelvic radiotherapy, or radiotherapy to >30% of
bone marrow.

- E 04. Adverse events (excluding alopecia and those listed in the specific exclusion
criteria) from any prior anticancer therapy of grade >1(National Cancer Institute
Common Terminology Criteria [NCI CTCAE] v4.03) at the time of randomization.

- E 05. Less than 18 years (or country's legal age of majority if the legal age is >18
years).

- E 06. Eastern Cooperative Oncology Group (ECOG) performance status >2.

- E 07. History of brain metastases, uncontrolled spinal cord compression, or
carcinomatous meningitis or new evidence of brain or leptomeningeal disease.

- E 08. Prior malignancy.

- E 09. Participation in another clinical trial and any concurrent treatment with any
investigational drug within 30 days prior to randomization.

- E 10. Any of the following within 6 months prior to study enrollment: myocardial
infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft,
New York Heart Association (NYHA) class III or IV congestive heart failure, stroke or
transient ischemic attack.

- E 11. Any of the following within 3 months prior to randomization: treatment resistant
peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory
bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled
thromboembolic event.

- E 12. Acquired immunodeficiency syndrome (AIDS-related illnesses) or known HIV disease
requiring antiretroviral treatment.

- E 13. Any severe acute or chronic medical condition which could impair the ability of
the participant to participate to the study or interfere with interpretation of study
results, or participants unable to comply with the study procedures.

- E 14. Absence of signed and dated Institutional Review Board (IRB)-approved
participant informed consent form prior to enrollment into the study.

- E 15. Participants with reproductive potential who did not agree to use accepted and
effective method of contraception during the study treatment period.

- E 16. History of hypersensitivity to docetaxel, or polysorbate 80.

- E 17. Inadequate organ and bone marrow function

- E 18. Contraindications to the use of corticosteroid treatment.

- E 19. Symptomatic peripheral neuropathy grade >2 (National Cancer Institute Common
Terminology Criteria [NCI CTCAE] v.4.03).

The above information was not intended to contain all considerations relevant to a
participant's potential participation in a clinical trial.